HyoSookHanMD

Breast Cancer

Senior member, Research Director

Overview of Dr. Han

Dr. Hyo Han is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from Seoul National University College of Medicine and has been in practice 18 years. She is one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. She has more than 70 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(563) 362-9232

Education & Training

University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2005 - 2008
Cleveland Clinic FoundationResidency, Internal Medicine, 2002 - 2005
Seoul National University College of MedicineClass of 1999

Certifications & Licensure

FL State Medical License 2008 - 2026
CA State Medical License 2004 - 2022
OH State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients Start of enrollment: 2013 Feb 06
Completed
Phase 1
COGNUTRIN in Breast Cancer Survivors Start of enrollment: 2014 Jul 30
Completed
Early Phase 1
Yoga for Aromatase Inhibitor-associated Joint Pain Start of enrollment: 2013 Sep 01
Completed
Not Applicable
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Start of enrollment: 2014 Sep 05
Completed
Phase 1, Phase 2
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer Start of enrollment: 2018 Feb 19
ACTIVE_NOT_RECRUITING
PHASE2
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) Start of enrollment: 2015 Jul 08
Completed
Phase 2
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Start of enrollment: 2017 Jun 23
Completed
Phase 1, Phase 2
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Start of enrollment: 2021 Sep 08
Recruiting
Phase 1
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
RECRUITING
PHASE2
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases Start of enrollment: 2021 Nov 30
RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer.
Hatem Soliman, Amy Aldrich, Neveen Abdo, Hyo Han, Aixa Soyano
NPJ Breast Cancer. 2025-03-17
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial.
Hyo S Han, Amy L Aldrich, Saurabh K Garg, R Jared Weinfurtner, Jonathan V Nguyen
JAMA Oncology. 2025-02-01
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Hope S Rugo, Mike Campbell, Christina Yau, A Jo Chien, Anne M Wallace
Breast Cancer Research and Treatment. 2025-02-01

Lectures

SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresect...
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Intratumoral Dendritic Cell Therapy Shows Promise in Early-Stage ERBB2-Positive Breast CancerDecember 9th, 2024
Vaccinex and Its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of CancerNovember 10th, 2022